Abstract Plain Language Summaries
At Pfizer, we know that many people actively seek the latest scientific developments related to medicines. Clinical data, however, can be complex and often difficult to understand if you are not a scientist. To help interested non-scientists better understand the latest research, we are developing summaries in plain language for research results presented at medical conferences. We call these “abstract plain language summaries” (APLS).
PLEASE NOTE: The APLS reports represent results of only one study. Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe to patients. The results might be different from the outcome of other studies that researchers have presented in the past. It’s also important to note that these data are investigational, and the treatments may not be approved in these settings by regulatory agencies.
Click the links below to access each APLS for the 2021 European Society of Medical Oncology (ESMO) Annual Meeting.
COVID-19 and Oncology
- A study of the BNT162b2 COVID-19 vaccine in people who have had cancer and took part in the global vaccine trial
- Time to chemotherapy after treatment with palbociclib plus hormone therapy in women with advanced breast cancer
- A study looking at the effectiveness and safety of palbociclib plus letrozole in Asian postmenopausal women with advanced breast cancer
- A real-world study looking at the treatment patterns of Black people, Indigenous people, and people of color (BIPOC) who took palbociclib for advanced breast cancer
- A real-world study looking at the effectiveness of palbociclib in combination with endocrine therapy compared to endocrine therapy alone in older patients with advanced breast cancer
- A review of how long people with hormone receptor-positive, human epidermal growth factor 2-positive (HR+/HER2+) advanced breast cancer live before their cancer starts to worsen and survive overall
- Response to talazoparib in people with breast cancer and faulty BRCA genes who previously received platinum chemotherapy
- Characteristics of people with advanced breast cancer who had blood-related side effects in the EMBRACA clinical trial
- General well-being in people with advanced breast cancer treated with Talazoparib
- Treatments and outcomes for people with prostate cancer in real-world settings
- Treatments people receive for prostate cancer in real-world settings and differences by age and metastatic site
- Do men with metastatic hormone-sensitive prostate cancer who took enzalutamide live longer than those who took placebo?
- Response to talazoparib in men with metastatic prostate cancer and faulty non-DNA repair genes
- Pain experiences in men with metastatic prostate cancer and faulty DNA damage repair genes who took Talazoparib
- Talazoparib and enzalutamide versus enzalutamide in men with metastatic, castration-sensitive prostate cancer and specific gene alterations (TALAPRO-3)
- Results from the HERO study: relationship between type of advanced prostate cancer and response to relugolix or leuprolide in men with advanced prostate cancer
- Results from the HERO study: effect of geographical location on response to relugolix or leuprolide in men with advanced prostate cancer
- 5-year update on COLUMBUS: a randomized phase 3 trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
- STARBOARD: randomized phase 3 study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma
- Gene changes that may cause lorlatinib to stop working in people with ALK-positive non-small cell lung cancer
- First-line Lorlatinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: Asian Subgroup Analysis of CROWN
- Lorlatinib dose modification for managing central nervous system side effects in people with non-small cell lung cancer